CKIa ablation induces p53 activation, and CKIa degradation underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome. Here we describe the development of CKIa inhibitors, which co-target the transcriptional kinases CDK7 and CDK9, thereby augmenting CKIa-induced p53 activation and its antileukemic activity. Oncogene-driving super-enhancers (SEs) are highly sensitive to CDK7/9 inhibition. We identified multiple newly gained SEs in primary mouse acute myeloid leukemia (AML) cells and demonstrate that the inhibitors abolish many SEs and preferentially suppress the transcription elongation of SE-driven oncogenes. We show that blocking CKIa together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferationmaintaining SE-driven oncogenes, and induce apoptosis. Leukemia progenitors are selectively eliminated by the inhibitors, explaining their therapeutic efficacy with preserved hematopoiesis and leukemia cure potential; they eradicate leukemia in MLL-AF9 and Tet2
SUMMARY
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ITD AML mouse models and in several patient-derived AML xenograft models, supporting their potential efficacy in curing human leukemia. Recent studies revealed the genomic landscape of the disease and pointed out its clinical and biological heterogeneity (Papaemmanuil et al., 2016) . Despite advances in our understanding of the disease, there has been no major progress in the standard therapy of AML in the past 40 years (Coombs et al., 2016; Shafer and Grant, 2016) . New avenues being developed for improving AML therapy include epigenetic modification of the leukemia cells by targeting chromatin regulators, such as IDH, HDAC, and BRD4 (Bradner et al., 2017; Ntziachristos et al., 2016) .
A different approach to AML treatment is by means of activating the tumor suppressor p53, which is mostly non-mutated in certain malignancies including leukemia (Papaemmanuil et al., 2016) . However, in many hematological malignancies including AML, p53 activity is suppressed due to multiple antagonistic mechanisms, most prominent of which is the activation of its major antagonist MDM2 (Kojima et al., 2016; Vogelstein et al., 2000) . Thus, major drug development efforts for p53 activation in cancer has been focused on MDM2 inhibitors (Levine and Oren, 2009) . Another robust way to activate p53 may be achieved by casein kinase 1A1 (CKIa) inhibition; this mode has been documented in vivo in mouse models of intestinal cancer (Elyada et al., 2011; Pribluda et al., 2013) and skin pigmentation (Chang et al., 2017) , in cultured leukemia cells (Jä rå s et al., 2014) , and was recently proposed as a mechanism of action of the thalidomide derivative lenalidomide, in the pre-leukemic human myelodysplastic syndrome (MDS) (Krö nke et al., 2015) . Lenalidomide, functioning as a molecular glue between the human E3 ubiquitin ligase cereblon and CKIa was shown to induce the ubiquitination and degradation of this kinase (Petzold et al., 2016) , thus presumably killing leukemic cells by p53 activation. While this approach indicates the therapeutic value for CKIa inhibition, it is limited to a small set of patients harboring one active allele of CK1a, such as in MDS of the del(5q) type (Krö nke et al., 2015) . Selective CKIa inhibitors should however reveal the full therapeutic potential of CKIa inhibition in cancer.
In an effort to develop selective small molecule CKIa inhibitors, we identified a unique class of kinase inhibitors, which as expected from knockout studies, stabilized b-catenin and p53. Unexpectedly, however, these inhibitors abolished the expression of the Wnt/b-catenin target gene Myc and the p53 master regulator and target gene Mdm2. Looking for an explanation, we found that the CKIa inhibitors co-target CDK9, the catalytic subunit of the transcription elongation factor P-TEFb, and CDK7, the catalytic subunit of the transcription factor TFIIH. Consequently, these inhibitors disrupt super-enhancers and thereby block the transcription elongation of multiple oncogenes. Robust p53 activation via CKIa inhibition and Mdm2 downregulation in combination with transcriptional shutdown of leukemia oncogenes, such as Myc, Myb, and Mcl1 provided an unprecedented therapeutic effect in different genetically engineered AML mouse models, as well as in patient-derived xenografts (PDX) of various AML subtypes.
RESULTS
Development of Small Molecule Pan-CKI Inhibitors
It has been reported that Csnk1A1 (CKIa) ablation compromises normal hematopoiesis and hypothesized that CKIa-deficient hematopoietic stem and progenitor cells (HSPCs) are eliminated via p53 activation (Schneider et al., 2014) . Here, we confirmed this hypothesis, showing that specific ablation of CKIa in the hematopoietic system via Mx1-Cre eliminated all the HSPCs, thus vacating the bone marrow (BM) niches for successful donor cells engraftment . This stem cell extinction function required wild-type (WT) p53, as co-ablation of CKIa and Tp53 (DKO) failed to eliminate the HSPCs ( Figure 1A ), nor did it allow hematopoietic rescue by bone marrow transplantation (BMT) ( Figure S1D ). This is likely due to occupation of the BM stem cell niches by persisting, yet non-functional DKO hematopoietic stem/progenitor cells, highlighting the importance of p53 activation.
Small molecule inhibitors may provide a therapeutic window to target leukemic cells despite lethal or adverse effects of a genetic deletion of the same target, a recent example being MCL1 inhibitors (Kotschy et al., 2016) . We therefore hypothesized that incomplete, intermittent CKIa inhibition with small molecules may spare normal HSPCs, based on the assumption that leukemia progenitors are more sensitive to CKIa inhibition (Jä rå s et al., 2014) . Of the myriad of small molecule CKI inhibitors identified, none have been proven to possess the capacity to efficiently block CKIa activity (Knippschild et al., 2014) . We therefore attempted to identify selective CKIa inhibitors via cell-based screening. These screens were based on a presumption derived from mouse CKIa ablation studies (Elyada et al., 2011) that small molecules found to stabilize both b-catenin and p53 in a responsive cell line might have CKIa blocking activity. Following massive cell-based screening of kinase inhibitor libraries in a colorectal cancer cell line (RKO), we focused on a small class of pyrazole-pyrimidine scaffold molecules (A-series), which, through intensive medicinal chemistry, yielded molecules with potent CKIa inhibitory activity ( Figures 1B-1F ). To confirm CKIa targeting, we measured compound binding to CKI family members and to the closely related CK2 family by kinome affinity matrix assay (DiscoverX Kinome Scan) and found that these compounds target all CKI members with sub-nanomolar affinity with the exception of A64 displaying high affinity only to CKId and CKIε; none of the compounds bound to CK2 ( Figure 1C ). We determined the structure of one of the potent CKI inhibitors, A86, with CKIa at 2.3 Å resolution ( Figure 1D ). A86 binds to the hinge backbone of the kinase via two hydrogen bonds between N1 and carbonyl of Leu93, N2 of 5-methylpyrimidine, and amide of Leu93. The cyclohexanamine and cyclopropane moieties are located at the entrance of the pocket and make hydrophobic interactions with Ile23 and Ile31, respectively. Moreover, the amine group of cyclohexanamine is hydrogen-bonded to OD2 of Asp99. Amino acids that form hydrogen bonds with the ligand in CKIa-A86 crystal structure (Leu93 and Asp99) are conserved over all the CKI family (but not in CK2) ( Figure S1E ). Indeed, co-crystallography of A86 with CKId (88% sequence homology with CKIa) indicated similar interactions at the active site ( Figure S1F ).
CKIa phosphorylates b-catenin on Ser45, priming its sequential phosphorylation by GSK3 on a set of conserved Ser and Thr residues in its N terminus, ultimately leading to b-catenin ubiquitination and degradation (Amit et al., 2002) . Similar to CKIa depletion, inhibitor treatment of RKO cells abolished most of the Ser45 phosphorylation signal and the consecutive GSK3 phosphorylation cascade resulting in stabilization of b-catenin (Figures 1E and 1F) . As CKIa modifies Ser45 uniquely (Amit et al., 2002) , it attests to the CKIa-inhibitory capacity of the molecules in live cells, a property that has not been documented before for other reported CKI inhibitors. CKIa ablation stabilizes p53 (Chang et al., 2017; Elyada et al., 2011) and induces DNA damage response (DDR), evident by H2AX phosphorylation, yet without evidence of DNA damage (Pribluda et al., 2013; unpublished data) . These features are reproduced by the A series inhibitors, in a dose-dependent manner, in correlation to their CKIa affinity (Figures 1C and 1F) . A64, unlike other A-series members, has low CKIa affinity, but high GSK3a/b affinity, and only induces p53 at a high concentration, possibly due to GSK3-inhibition-mediated b-catenin stabilization (Damalas et al., 1999) ( Figures 1C and 1F) ; therefore, it is often used in our functional assays as a negative control. Together, our findings affirm that these A-series molecules are pan-specific CKI inhibitors with discernible CKIa inhibitory activity.
Selective Anti-leukemic Activity of CKIa Inhibitors in the MLL-AF9 AML Mouse Model We then asked whether the inhibitors, unlike genetic deletion of CKIa ( Figure 1A ), are able to distinguish leukemic from normal hematopoietic stem cells. We first tested A-series inhibitors for apoptotic killing ability against primary leukemic BM cells isolated from MLL-AF9-induced AML mice, representing a poorprognosis human acute leukemia (Barabé et al., 2007) . Of the six compounds, four (A86, A51, A75, and A14) were found to be highly effective in inducing leukemia cell apoptosis at 160 nM or lower (Figure 2A ), mostly in correlation to their capacity to stabilize p53 ( Figure 1F ). We tested the selectivity of one of these apoptosis-inducing inhibitors in a methylcellulose colony-forming unit (CFU) assay. At the nanomolar concentration range tested, A51 did not affect normal hematopoietic CFUs. However, leukemic CFUs were highly sensitive to the inhibitors with an IC 50 below 9 nM ( Figure 2B ), indicating a selective anti-leukemic activity of the inhibitor. Treatment of cKit + leukemia progenitors, highly enriched in leukemic stem cells (LSCs) (Somervaille and Cleary, 2006) , indicated that this population is as sensitive to inhibitor killing as the cKit À cells ( Figure S2A ). dose treatment. Remarkably, 5-6 hr post treatment, robust DDR, p53, and cleaved caspase 3 activation were already evident in leukemic BM cells (Figures 2C and S2J) . 16 hr post treatment with A51 or A86, leukemic cell counts (GFP + ) in BM and peripheral blood (PB) were down to 5%-10%, accompanied by massive reduction of the spleen mass and reduced cellularity and color change of the bone marrow due to leukemia cell apoptosis ( Figures 2D, 2E , and S2B-S2I). Tissue survey showed that whereas the treatment relieved most of the leukemia signs from the BM, spleen, liver, and PB, non-leukemia-involved tissues, such as the intestine, heart, and lungs, were unaffected by this short-term treatment ( Figures 2F, 2G , S2K, and S2L). These findings attest to a selective and abrupt in vivo sensitivity of AML cells to the CKI inhibitors.
Pharmacokinetic studies of the inhibitors A14, A51, and A86 at 20 mg/kg revealed rapid oral absorption with a T max of 0.2-2 hr, C max of 1,060-1,610 ng/mL, T 1/2 of 1.9-4.3 hr, and area under the curve (AUC) values of 2,510-3,680 (ng*hr/mL) ( Figure 3A) . These values represent moderate plasma clearance, on which basis we chose A51 and A14 for a long-term treatment study. To determine the maximal tolerated dose (MTD), we first tested the 7-day effects of daily A51 and A14 treatment at 20 mg/kg or below in normal C57BL/6 mice. While treatment doses of both inhibitors above 10 mg/kg transiently reduced the white blood cells (WBC) and platelet counts (not shown), at 5-10 mg/kg, there was no adverse effect on hematopoiesis ( Figure S3A ; data not shown) nor did we observe any signs of toxicity in hematopoietic and other tissues by histology ( Figure S3B ). Treatment of a comparable therapeutic dose range in rats and dogs was also well-tolerated ( Figures S3C and S3D ). Furthermore, hERG inhibition assay of A51 indicates no cardiotoxicity at the therapeutic dose range and is non-mutagenic in AMES test ( Figure S3E ).
We then tested long-term anti-leukemic effects of the inhibitors in MLL-AF9-driven AML mouse model. Oral treatment was initiated at either 8 days (for A51) or 4 days (for A14) after leukemia cell inoculation, at which the percentage of leukemia cells in the BM was more than 1.5% of all cells (data not shown). Whereas all vehicle-treated mice showed leukemic cell infiltration into the peripheral blood (PB) within 2-3 weeks post-inoculation and most succumbed to the disease within a month, no leukemic cells were observed in PB of treated mice before 3 weeks ( Figures 3B and 3C ). Forty to fifty percent of the A51-or A14-treated mice survived with no signs of disease up to 5 months observation ( Figures 3D and 3E ) nor had any sequela of long-term treatment; all A51-treated mice had normal organ morphology and histology ( Figure 3F ) and normal blood counts ( Figure S3F ).
Long-term leukemia-free survival with possible cure depends on elimination of leukemia-propagating cells, or LSCs, which are often resistant to treatment (Abraham et al., 2016) . Functional assessment of residual LSCs following leukemia treatment is possible by transplantation of BM cells from treated mice to lethally irradiated normal mice. This procedure also assesses preservation of normal HSPCs after treatment. Transplantation of BM pooled from several long-term A51-treated surviving AML mice into lethally irradiated WT mice led to mouse rescue with full reconstitution of the hematopoietic system (Figures 3G and 3H) . None of the transplanted mice showed any evidence of leukemia at an observation period of 4 months, attesting to selective elimination of LSCs ( Figure 3I ).
The CKI Inhibitors Co-target CDK7 and CDK9 Observing a potent and selective effect of the inhibitors in leukemic cells, but not in normal cells at the treatment dose, prompted us to elucidate the molecular basis for this distinction. We speculated that this might stem either from partial CKIa inhibition, which does not compromise the normal function of HSPCs, or from additional properties of the CKI inhibitors, which selectively affect leukemia cells. Lenalidomide, a thalidomide analog, which functions as a protein homeostatic modulator (PHM) linking CKIa to the human E3 ligase cereblon, induces CKIa degradation exclusively in human cells (Krö nke et al., 2015) . We developed a thalidomide analog, BTX161, which mediates degradation of CKIa better than lenalidomide in human AML cells and activates DDR and p53, while stabilizing the p53 antagonist MDM2 (Figures 4A and 4B ). In contrast, the catalytic CKIa inhibitors revealed a fundamental difference-A51 and A86 abolished the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1 ( Figure 4B ). Suppression of MDM2 and MYC protein levels by A51 was also reproduced in RKO cells, even on top of CKIa knockdown and proteasome inhibition, which stabilize both proteins ( Figure S4A ). mRNA analysis echoed the protein assay, showing that A51 and A86 induced a marked reduction in mRNA expression of MYC and MDM2, yet upregulated the expression of the Wnt targets AXIN2 and CCND1 (Cyclin D1). In contrast, BTX161 upregulated all the Wnt targets including MYC and did not affect MDM2 mRNA expression (Figure 4C) . The observed disparity of CKIa-degrading PHM and the catalytic inhibitors in regulating MYC and MDM2 expression suggest that the catalytic inhibitors have additional targets, a common property of many small molecule kinase inhibitors (Klaeger et al., 2017; Knight and Shokat, 2005) . Based on observing the effect on MYC and MDM2 at the mRNA level, we hypothesized that these CKIa kinase inhibitors might also target a transcriptional kinase. To identify relevant targets, we measured the binding of leukemia-active and inactive A-series inhibitors to the major transcriptional kinases. Interestingly, the active compounds A51 and A86 targeted 2 of 7 known transcriptional kinases, showing high inhibition of CDK7 (TFIIH) and CDK9 (P-TEFb) but hardly any inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19 ( Figure S4B ). CDK7 phosphorylates the carboxy-terminal domain (CTD) of RNA polymerase II (RNA Pol II) at Ser5 and Ser7, enabling transcriptional initiation. Then, transcription is paused until positive transcription elongation factor (P-TEFb)/CDK9 phosphorylates RNA Pol II CTD at Ser2, facilitating transcription elongation (Zaborowska et al., 2016) . Direct binding affinities showed that the active A-series inhibitors, A51 and A86, target both CDK7 and CDK9 with low nM K d values, whereas the inactive one, A64, binds CDK7 moderately, but CDK9 poorly ( Figure 4D ). CDK7 (catalytic subunit of TFIIH), and in particular CDK9 (catalytic subunit of the transcription elongation factor P-TEFb), are considered as gatekeepers of the transcriptional machinery (Winter et al., 2017) , and clinical trials with small molecule inhibitors of these kinases are underway (Ferguson and Gray, 2018) . To implicate CDK7 and CDK9 in leukemia repression, we tested the inhibitory activity of A51, A86, and the inactive analog A64 on Pol II CTD phosphorylation at Ser2 and Ser5 in primary mouse and MV4-11 human AML cells ( Figures 4E and S4C ). We observed that A51 and A86, but not A64, induced a marked reduction in the corresponding phosphorylation signals, in correlation with their potency of repressing MCL1 and MYC expression ( Figures 4E and S4C ). qPCR analysis in mouse primary AML BM cells revealed a significant reduction of Myc, Mdm2, and Mcl1 mRNA expression post A51 and A86 treatment, but not by A64 ( Figure 4F ). In contrary, the mRNA expression of the Wnt target gene Axin2 was enhanced, signifying there is no global shutdown of transcription. We therefore presumed that blocking the transcriptional kinases CDK7 and CDK9 might be a major contributing factor in the downregulation of MYC, MDM2, and MCL1. Importantly, phospho-CTD inhibition with downregulation of MCL1 and activation of p53, DDR, and caspase 3 was observed in vivo after single oral treatment of leukemic mice with A51 or A86 (Figures 4G and 4H) , suggesting that CDK7 and CDK9 inhibition plays an essential role in leukemic cell apoptosis. In common with most other small molecule kinase inhibitory drugs (Klaeger et al., 2017) , the CKIa-CDK7/9 inhibitors target other protein kinases. Compilation of all the protein kinase hits at 100 nM reveals an aggregated list of 34 targets for all six A-series derivatives ( Figure S4D ). However, upon correlating the hits with the potency of these derivatives to induce leukemia cell killing and apoptosis-related signaling, CKIa and the transcriptional kinases CDK7 and CDK9 stand out among the most relevant targets. Kinases hit by both active and inactive compounds, such as the JNK family and ERK8, are likely of secondary importance. To understand the structural basis for co-targeting CKIa and CDK9, we determined the structure of P-TEFb (CDK9-cyclin T1 complex) with A86 at 3.2 Å resolution ( Figure 4I ). An overlay of the crystal structures of CKIa and CDK9 with the same ligand shows that both the configuration of the inhibitor within the ATP binding pockets of these two kinases and the hydrogen bond array, which holds the inhibitor in the two ATP pockets, are very similar ( Figure 4J ). A86 binds at the ATP pocket of CDK9 with the N2 and N1 of the fluoro-pyrimidinamine moiety, which participate in hydrogen bonding to the hinge region main chain oxygen and main chain nitrogen of residue Cys106. The spatially adjacent amino acid, Asp109, stabilizes the cyclohexanamine moiety via a hydrogen bond between N atoms ( Figure 4I ).
The CKIa-CDK7/9 Inhibitors Abolish Super-Enhancers and Preferentially Block Super-Enhancer-Driven Transcription Elongation Considering that the transcription of many oncogenes, like Myc, is amplified in leukemia due to a strongly activated enhancer denoted super-enhancer (SE) (Bradner et al., 2017; Lové n et al., 2013) , and SEs are sensitive both to CDK7 and CDK9 inhibition (Ferguson and Gray, 2018) , we thought that part of the antileukemic effect of the inhibitors might be via SEs disruption. A common tool for assessing SE regulation is the acetylation of H3K27, which is highly enriched in SEs (Lové n et al., 2013) . Global SE assessment of MLL-AF9-driven AML BM cells (Figure 5A ) versus normal mouse BM cells ( Figure S5A ), revealed robust SE gains (de novo SE generation) (Bradner et al., 2017; Ntziachristos et al., 2016) in mouse AML BM cells. Many of these gains are associated with common leukemia drivers, among which are Myb, Myc, Runx2, and Meis1, scoring high in the AML hockey stick plot ( Figure 5A ). Of the 342 SE-associated genes identified in AML BM, 37% (125) were specifically gained in AML (AML-specific) ( Figures 5A, S5A , and S5B). Upon A51 treatment, H3K27Ac in SE-associated genes was reduced, and many SEs were virtually abolished ( Figures 5B and 5C ). Of note, although certain enhancers like Cdk6 and Baz2b pass the threshold to be considered as SEs in WT BM ( Figure S5A ), their acetylation densities and corresponding scores on the ''hockey stick'' plots are undoubtedly amplified by at least 30-to 50-fold in MLL-AF9 leukemic cells (see Figures 5C and S5C for a few detailed examples). Interestingly, our global analysis also revealed a few SE gains linked to genes that are not commonly associated with leukemia, among which is the IKAROS family gene Ikzf2/Helios ( Figure 5C ) and the bromodomain-encoding gene Baz2b ( Figure S5C ), both fully abolished by A51 treatment. The transcriptional shutdown of these SE-associated genes in A51-treated AML cells was confirmed by mRNA analysis for major leukemia drivers such as Myb, Erg, and Cxcr4 ( Figure 5D ).
Super enhancers forcefully drive the transcriptional elongation of their target genes (Henriques et al., 2018) , which may be curtailed by P-TEFb/CDK9 inhibition. To further test the effect of the inhibitors on transcription elongation, we ran a genomewide analysis of pSer2 CTD chromatin immunoprecipitation sequencing (ChIP-seq) in ex vivo treated (A51 and control DMSO) primary BM cells isolated from MLL-AF9-driven AML mice in biological duplicates. Indeed, upon A51 treatment, we observed a marked downregulation of Pol II Ser2 CTD phosphorylation at SEs versus typical enhancers (TE) ( Figure 5E ). A few examples demonstrating pSer2 suppression downstream of the transcriptional start sites of SE-regulating genes (Figures 5F and S5D) attest to a block in transcription elongation.
Combinatorial Action and a Rapid Hit Mechanism of the Inhibitors A significant number of the AML-specific SE gains abolished by the inhibitors treatment are involved in apoptosis control, suggesting that blocking CKIa together with either CDK7 or CDK9 may augment the apoptotic effect of p53 in leukemia cells. To test this presumption, we treated MV4-11 cells with CKIa degrader BTX161 in combination with the specific CDK9 inhibitor iCDK9 (Lu et al., 2015) , with THZ1, a potent, specific CDK7 inhibitor (Kwiatkowski et al., 2014) , or with both iCDK9 and THZ1. As expected, the transcriptional inhibitors THZ1 and iCDK9 reduced the pSer2/5 CTD, but at the tested concentration, had individually little effect on DDR, p53, and caspase 3 activation. BTX161, on its own, augmented p53 and MDM2 protein expression, yet in combination with THZ1, and particularly with both THZ1 and CDK9, further augmented p53 and induced maximal caspase 3 activation ( Figure 6A ). Remarkably, monotreatment with A51 surpassed all the combination effects, underscoring the value of intense co-targeting CKIa and the transcriptional kinases CDK7/9 by the A-series inhibitors for optimal anti-leukemic effect. Typical administration of kinase inhibitors for the treatment of cancer requires a protracted, continuous daily schedule to achieve above-threshold therapeutic plasma concentration. This is reflected in the AUC value, which correlates with the efficacy and toxicity of the treatment (Widmer et al., 2014) . Whereas PK studies of our inhibitors show only moderate AUC values with T 1/2 up to 4 hr ( Figure 3A ), the therapeutic efficacy was very high. This implies that unlike most kinase inhibitors, the CKIa-CDK7/9 inhibitors may only require intermittent short exposures in order to achieve long-term therapeutic efficacy. To study this presumption, we exposed primary mouse MLL-AF9-driven AML cells to a range of inhibitor concentrations for limited time intervals, followed by washout, and analyzed the signaling effects of the inhibitors 6 hr after application. Elimination of Pol II Ser2/Ser5 CTD phosphorylation and the leukemia oncogenes MCL1 and MDM2 was almost complete, whether treated for 5 min or 6 hr ( Figure 6B ). These rapid-hit data were also reproduced in a human colorectal RKO cell line ( Figure 6C ). In contrast to SEs targets, maximal b-catenin stabilization in these cells was only achieved upon continuous inhibitor treatment ( Figure 6C ), ruling out prolonged intracellular persistence of the inhibitor after short exposure. The efficacy of this rapid-hit action was dose-dependent: higher doses of A51 were effective within a few minutes, whereas lower doses required longer times (Figures 6B and 6C) . Importantly, a similar rapid-hit effect was also observed in an ex vivo AML killing assay, when 5 mins exposure to A51 and A86 was sufficient to induce significant AML cell killing (Figure 6D) . Protracted shutdown of AML-gained SEs upon brief inhibitor exposure likely contributes to the in vivo therapeutic effects-leukemia eradication with no adverse effects under the MTD.
Anti-leukemic Activity of A51 in AML Mouse Models of Tet2
ITD -Driven and Patient-Derived Xenografts AML is a heterogeneous disease ignited by a variety of mutations and bearing different vulnerabilities. FLT3 is the most abundant AML driver mutation; $30% of AML patients harbor this mutation (Papaemmanuil et al., 2016) . Hence, we further tested our inhibitors in a mouse model in which Flt3 ITD mice were crossed with Tet2 À/À mice, inducing lethal AML (Shih et al., 2015) . Daily oral A51 treatment (6 days a week) for 3 weeks ameliorated the disease profoundly, similarly, or better than the FLT3-multikinase inhibitor midostaurin, reducing the total peripheral WBC, spleen mass, and leukemia blasts occupancy of the bone marrow and spleen while preserving almost normal levels of RBC and platelets (Figures 7A-7C and S6A-S6D). Moreover, blood and tissue infiltration with leukemia cells were strongly reduced by the inhibitor (Figure S6E) . Notably, the BM cKit Hi CD11b
Low leukemic progenitor cells were almost completely eliminated by the inhibitor ( Figure 7D ). Figure 7F ).
After demonstrating a profound effect of our inhibitors in two different AML mouse models, we sought to check the effect in human AML. First, we tested the ex vivo killing effect in primary human leukemia cells from 5 individual patients with distinct genotypes. Our results show leukemia cell apoptosis by A51 and A86, but not by A64 or midostaurin at comparable inhibitor concentrations ( Figure S6G ). Killing effect was achieved at a low IC 50 of 20-50 nM in all 5 samples. Next, we went on to test the effect of lead compound A51 in patient-derived xenograft (PDX) mouse models. Three xenograft models representing different human AML subtypes were established in NSG mice and treated for 2.5-5 weeks with A51 or vehicle, then sacrificed and assessed for anti-leukemic effects. PDX-1 model established from secondary AML patient was also treated for comparison with the standard AML chemotherapy cytarabine, and the leukemia burden was monitored weekly by flow cytometry analysis of PB human myeloid leukemia cells (hCD33). Leukemia was well-controlled in A51-treated mice, whereas all vehicle-control mice, as well as cytarabine-treated mice succumbed to leukemia at 3-5 weeks of treatment ( Figure 7G ). Moreover, human leukemia-derived WBCs were profoundly reduced, accompanied with mouse WBC enrichment ( Figure 7H and data not shown) and normalized counts of RBCs and platelets in 5-week A51-treated mice (Figures S7A and S7B) . Analysis of hCD33 showed a strong anti-leukemia effect in whole blood and the spleen, yet not in the BM, possibly due to a late phase relapse ( Figure S7C ). PDX-2 mice also developed myeloid leukemia. Following A51 treatment for 3 weeks, all hCD33 + , hCD45 + , and hCD38 + cells were eliminated, whereas mCD45 + cells were enriched up to 90% in the BM of all treated mice (Figures 7I, 7J, S7D, and S7E). Ex-vivo treatment of BM cells from PDX-2 inoculated mice shows the typical molecular response pattern observed in the non-human leukemia mouse models, including downregulation of MCL1 and MYC and activation of p53 and caspase 3 ( Figure 7K ). PDX-3 grew as a myelosarcoma at the injected leg muscle with typical morphology (Wilson and Medeiros, 2015) ( Figure S7F ). Histology and IHC staining for hCD45 and hcKit show human granulocytic leukemia cells ( Figure S7G ). All treated mice demonstrated a good response to A51 therapy (Figures S7F and S7H-S7K) with evidence of apoptosis in H&E and cleaved caspase 3 immunostaining ( Figures S7J and S7K) . Together, our PDX data consistently indicate a strong therapeutic effect of A51 in human leukemia samples of different disease subtypes.
DISCUSSION
To date, a notable disadvantage of all drug treatment modalities in human AML is either poor response or rapid relapse following short remission (Dombret and Gardin, 2016) . Our studies show that small molecules with a capacity of targeting both CKIa and the transcriptional kinases CDK7 and CDK9 have a striking therapeutic effect in different AML mouse models, with high potential of curing rates. We observed elimination of leukemic stem cells without affecting normal hematopoietic stem cells, evident by secondary BM transplantation from treated MLL-AF9 AML mice. In addition, we show profound anti-leukemic effects of our kinase inhibitors in Tet2 À/À ;Flt3 ITD -driven AML mice. Remarkably, the lead inhibitor A51 performed also well in multiple AML PDXs, including a highly aggressive human secondary leukemia, which is a prominent therapeutic challenge (Boddu et al., 2017) . The therapeutic advantage of our inhibitors stems from a synergistic pro-apoptotic activity of two main targeted pathways, CKIa and CDK7/9 SE-regulated. We have shown that CKIa ablation provokes a DNA damage response and p53 activation, yet it also induces pro-leukemic Wnt activation and upregulation of Myc and Mdm2, some of the most established driver oncogenes in various hematological malignancies (Delmore et al., 2011; Kojima et al., 2016) . Fortuitously, triple inhibition of CKIa and the transcriptional kinases CDK7 and CDK9 cancels these pro-leukemic effects, while accentuating synergistic p53 activation and its pro-apoptotic activities. This synergism was also documented by combination treatment of our newly developed CKIa-degrading molecule BTX161 with either one of the selective inhibitors of the transcriptional kinases CDK7 and CDK9, and even better with both transcriptional kinase inhibitors. It underscores the advantage of the dual-purpose inhibitors, in comparison to p53 exclusively based leukemia treatment (Kojima et al., 2016) as the latter are likely moderated by SE-driven antagonism. In line with this presumption, p53 activation has been shown to cooperate with Myc inhibition in eliminating chronic myelogenous leukemia-initiating cells (Abraham et al., 2016) . Notably, in common with all the clinically tested kinase inhibitors (Klaeger et al., 2017) , including the most selective ones, our A-series inhibitors target more than 3 kinases, and although these triple specificity correlates very well with the anti-leukemic potency of the inhibitors, we cannot exclude the contribution of other inhibitor targets to the therapeutic activity. A particularly attractive target is DYRK1A, which has a high affinity to the active inhibitors. This kinase was recently shown to phosphorylate RNA Pol II CTD Ser2/5 alternatively to CDK7/9 and to complement these two kinases in RNA Pol II phase separation, which augments transcription rates (Lu et al., 2018) . In fact, having moderate rather than strict selectivity and targeting multiple pathways may overcome target redundancy, preventing the emergence of resistant leukemia clones in line with the enhanced cure rates (Klaeger et al., 2017) . In addition, in a heterogeneous disease like AML, kinase-related vulnerabilities may variably synergize with each other in different AML types. SEs have recently been highlighted as attractive targets for epigenetic therapy of cancer, particularly in hematological malignancies, and are subject to bromodomain-BET, CDK7, and CDK9 inhibitors (Bradner et al., 2017; Dawson et al., 2011; Delmore et al., 2011; Ferguson and Gray, 2018) . Whereas SEs drive the expression of multiple genes in normal and leukemic stem cells, our analysis revealed many SEs that were newly gained in AML versus normal BM. Many other leukemia SEs that have counterparts in normal BM are markedly amplified in the primary AML cells. Among the newly gained and highly amplified SEcontrolled genes, we identified the well-recognized leukemia oncogene drivers Myc, Myb, and Runx2, as well as genes that are not commonly associated with leukemia. Examples include the IKAROS family gene Helios, which was previously implicated in leukemic stem cell control and cancer immunity evasion in mouse models (Park et al., 2015; Nakagawa et al., 2016 ) and a bromodomain-encoding protein Baz2b, which could possibly function as a new SE component. These, similarly to most other identified leukemia SEs, were nearly abolished or highly suppressed by the CKIa-CDK7/9 inhibitor treatment. In addition, genome-wide analysis of primary AML cells through pSer2 CTD ChIP revealed that the transcriptional elongation of SEregulated genes was far more repressed by the inhibitor treatment than elongation regulated by typical enhancers, again demonstrating a particular vulnerability of SE-controlled transcription that prevails in leukemia cells.
A major challenge to the development of new anticancer drugs is finding a therapeutic window (i.e., dose-dependent therapeutic efficacy with manageable toxicity). This window depends on the relative vulnerabilities of cancer cells versus normal cells of different tissues. Two related parameters seem to favor leukemia vulnerability to our triple inhibitors: leukemia addiction to SEassociated oncogenes, which sensitizes it to the inhibitors far more than normal cells, and the rapid-hit mechanism of action of the CKIa-CDK7/9 inhibitors, at variance with the occupancydriven pharmacology paradigm that prevails in the kinase-inhibitor arena (Salami and Crews, 2017) . These two parameters are likely interdependent: the ability to disrupt SEs and eliminate their associated oncogenes for many hours after a few minutes of drug exposure enables short intermittent therapy with long pauses, which may minimize generalized toxicity. This is substantially different from ordinary chemotherapy, which may also kill cancer cells instantly via different mechanisms, yet is far less selective in discriminating malignant from normal cells. In addition, unlike chemotherapy, our inhibitors induce DNA damage response and p53 activation without overt signs of DNA damage (Pribluda et al., 2013 ; unpublished data), a further explanation to the paucity of undesired effects within the therapeutic range. Indeed, at the therapeutic dose, we did not observe in our AML mice any significant adverse treatment effects even at daily treatment of 45 days. Likewise, our data show that the MTD and safety profile of the inhibitors at a mouse-comparable therapeutic dose range in rats and dogs are similar to those in mice; other toxicity indices, such as the cardiotoxicity index hERG and performance at the AMES mutagenesis assay score are well within the acceptable safety range. Inhibitors with similar properties may therefore prove suitable for the treatment of AML patients and possibly other human cancer types, particularly those that similarly to AML show SE-linked transcriptional addiction and likely to benefit from p53 activation.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
All experiments were performed in accordance with the guidelines of the institution ethics committee (AAALAC standard). For human samples, the institutional review board of Hadassah Hospital Medical Center approved the use of these samples (0416-16-HMO), according to the principles of the Helsinki Declaration. Informed consent was obtained from all patients prior to performing these experiments.
Mice
Mice with a genetically modified Csnk1a1 locus (floxed exons 1 and 2 of the mouse Csnk1a1 gene) (Elyada et al., 2011) (Junttila et al., 2010) . p53 KI/KI , Mx1-cre transgenic mice and CD45.1 WT C57BL/6 were purchased from Jackson lab. All experiments were performed on male or female mice in similar numbers as our initial data did not indicate significant differences in disease progression or response to treatment between females or males.
Health/immune status All mice were kept under SPF conditions at the Hadassah Medical School animal facility unit of the Hebrew University and were regularly screened for standard pathogens. All experiments were performed in accordance with the guidelines of the institution ethics committee (AAALAC standard). All mice were drug and test naive prior to initiating the experimental procedures performed and described in this paper.
Cell cultures RKO cells were grown in DMEM supplemented with 10% Serum. Cells were transduced with shRNA lentiviral vector for 4-7 days. MG132 (20 mM; Calbiochem) was added for 4 h before cell harvesting. MV4-11 human AML cells were grown with RPMI supplemented with 10% Serum. Both cell lines were obtained from ATCC collection (RKO: ATCC CRL-2577, MV4-11: ATCC CRL-9591) without further authentication. RKO sample obtained from a female patient, MV4-11 cells are from a male patient. All other sample specifications are found in the ATCC database.
Human primary cells
All human primary cells were obtained from newly diagnosed AML patients prior to treatment. Following BM biopsy, bone marrow derived mononuclear cells (BM-MNC) were extracted by Ficoll and either used directly or frozen for later usage. For defrosting cells were thawed directly into Iscove's Modified Dulbecco's Medium (IMDM) with 50% FBS and DNaseI (10 mg/ml). Cells were spun and resuspended in RPMI supplemented with 10% FBS (GIBCO, #12657), L-Glutamine, Pen/Strep (Biological Industries, Israel), IL-6 (20 ng/ml), IL-3 (10 ng/ml), GM-CSF (100 ng/ml) and TPO (10 ng/ml) (Peprotech). Cells were incubated with the inhibitors for 18-20 hr, and then analyzed for cell apoptosis by FACS. For blast cell identification anti-human CD45 antibody (eBioscience #304022) was added before analysis. For mRNA expression analysis, cells (sample #5546) were incubated with the inhibitors for 4 hr and analyzed by RT-PCR. 5 human samples with distinct genotypes were used for estimating the inhibitor cytotoxicity: 
METHOD DETAILS
Development of small molecule CKI inhibitors (SMI) SMI were developed by an initial cell-based screening followed by extensive medicinal chemistry (see Compound Synthesis). Primary high throughput screens were run in RKO colorectal cancer cells, looking for b-catenin stabilization. RKO cells were plated onto 394 well plates, treated with the compounds at 10 mM for 16hrs. Treated cells were tested for accumulation of nuclear b-catenin by immunostaining (IF) using mouse anti-b-catenin antibodies (BD, Cat# 610154) and Donkey anti Mouse Alexa 488 as a secondary antibody (ThermoFisher, Cat# A21202). Cells treated with the proteasome inhibitor MG132 (10mM) served as the b-catenin stabilization high control and DMSO (the vehicle for compounds and for MG132) as a basal level control. Cell viability was monitored using CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat# G7570). Compounds scoring positive for accumulation of nuclear b-catenin were selected for a secondary screen. The secondary assay was performed by western blot analysis of treated RKO cells, looking for compounds stabilizing both b-catenin and p53 and inducing histone H2AX phosphorylation (indicators of CKIa deficiency; see Elyada et al., 2011) .
Kd determination
The binding affinity of all compounds was determined using KINOMEscan at DiscoverX. Test compounds were prepared in DMSO and Kds were determined using an 11-point 3-fold compound dilution series with three DMSO control points. KINOMEscan Kd were generated as described previously (Fabian et al., 2005) . Similarly, primary binding interaction screens were performed to evaluate '% Ctrl', which were further used to estimate Kds.
Negativecontrol = DMSO ð100% CtrlÞ
Positivecontrol = controlcompound ð0% CtrlÞ AML mouse models and inhibitor treatment 1. MLL-AF9 AML mouse model To generate the MLL-AF9 driven AML mouse model we followed the protocol generated by (Barabé et al., 2007) . BM from WT C57BL/6 was extracted and enriched for c-Kit expressing cells (EasySep) and incubated overnight in RPMI supplemented with 15% FCS, L-Glutamine, Pen/Strep (Biological Industries, Israel), stem cell factor (SCF), IL-3, IL-6 and TPO (Peprotech). BM cell culture was infected with retrovirus MLL-AF9-IRES-GFP for 4 hr and then incubated with culture medium for 24 hr. Infected BM cells were then injected I.V. into sublethally irradiated mice (500 rad; X-RAD 225 from PXi precision X-ray). Moribund mice were sacrificed and their BM was extracted. 50,000 BM GFP + cells were injected I.V. into C57BL/6 WT (8 -12 weeks old, males and females, approximately in similar numbers) irradiated (250 rad) mice.
To test acute effects of the inhibitors, mice with advanced disease (> 80% GFP + cells in PB) were treated with a single oral administration of the specific inhibitor and sacrificed at several short time points. For long-term therapeutic effects, mice were orally treated by gavage daily with either A51 (Di-HCL salt) (starting day 8-post inoculation, 5mg/kg per day, 6 days a week for 25 days) or with A14 (Di-HCL salt) (starting day 4 post leukemia inoculation, 10mg/kg per day, 6 days a week for 25 days) or vehicle.
To assess possible leukemia cure following treatment, BM (CD45.2) from rescued mice (135 days post leukemia inoculation) were pooled and 5 3 10 6 cells were transplanted I.V. into lethally irradiated (950 rad) CD45.1 recipient WT mice. Mice were followed for up to 5-month post bone marrow transplantation (BMT) for successful engraftment and survival. This experiment was repeated twice, each time with BM pooled from 3 rescued mice derived from two different experiments. Control lethally irradiated (950 rad) CD45.1 recipient WT mice were transplanted with BM pooled from 3 mice that developed leukemia after cessation of treatment. (Shih et al., 2015) . Seven days post leukemia inoculation, mice were orally (gavage) treated with either A51 (Di-HCL salt) (5mg/kg), midostaurin (35mg/kg) or vehicle for 18 days (6 days a week) and were sacrificed 9 days after stopping the treatment. . NSG-SMG3 mice were irradiated (225 rad) and transplanted intra-femoral (IF) with 1 3 10 6 leukemic cells with normal karyotype, NPM1+, FLT3-ITD+, FLT3-TKD-5 weeks after transplantation, PDX-2 and PDX-3 mice were treated orally for 2.5-3 weeks, 5d/week with A51 (Di-PTSA salt) (7.5mg/kg) or vehicle. Following treatment, mice were sacrificed and analyzed for leukemia spread to the bone marrow, spleen and other organs.
All the PDX studied (PDX1, 2 &3) were from newly diagnosed AML patients prior to treatment.
Drug Safety Assessment
Rats. Three groups of rats (10 rats per group, 5 males and 5 females) were administered A51 (Di-PTSA [p-Toluenesulfonic acid] salt) once daily for up to seven consecutive days at dosages of 1 or 3 mg/kg/day (all within the mouse therapeutic dose range) or vehicle (DMSO 10%, Solutol 10% and 2-hydroxy prolyl-b-cyclodextrin (HP-b-CD, 10% w/v) in ultra-pure water) and evaluated for clinical signs of toxicity and body weight. All animals in the 0, 1, and 3 mg/kg/day groups survived until scheduled termination and were euthanized on Day 8 for collection of hematology and serum chemistry samples, and postmortem examination. Organs were weighed, and tissues preserved and retained in fixative without further processing or evaluation. Dogs. Four groups of four dogs (two per sex per group) were administered with vehicle or A51 (0.2 or 0.6 and 2.0 mg/kg/day, corresponding to the mouse therapeutic dose range and twofold beyond) once daily for up to seven consecutive days. Animals were evaluated for clinical signs of toxicity, body weight, and food consumption, and samples for evaluation of systemic exposure to A51 were collected from available animals on Days 1 and 7. On Day 8, surviving animals were euthanized and subjected to macroscopic examination, including organ weights and tissue collection/preservation.
In vivo and ex vivo treatments
For in vivo use (mouse oral treatment), A-series compounds (Di-HCL salts) were dissolved and administered in 1% methyl cellulose (sigma) in pure water, together with 0.01% tween 80 (sigma) and 0.02% PEG400 (sigma). For the PDX experiments, A51 Di-PTSA salt was dissolved and administered in DMSO 10%, Solutol 10% and 2-hydroxy prolyl-b-cyclodextrin (HP-b-CD, 10% w/v). For tissue culture experiments, compounds were dissolved at 1000X stocks in Dimethyl sulfoxide (DMSO) and diluted in growth medium. PKC412 (midostaurin) 6% w/w in Gelucire 44/14 (Gattefosse, France) was stored at 4 C as a waxy-solid formulation. Prior to administration, the Gelucire/PKC412 waxy solid mixture was warmed in a 44 C water bath until liquid. The liquid mixture was then diluted with sterilized deionized water to produce the final PKC412 concentration. Dosing was performed 6d/week for 3 weeks by gavage at a concentration of 35mg/kg.
Crystallography studies
Crystals of CKIa (2.3 Å ), CKId (1.6 Å ) and P-TEFb (CDK9/Cyclin T1) (3.2 Å ) in complex with A86 were obtained using sitting drop vapor diffusion set-ups and datasets were collected at the ESRF synchrotron radiation source (Grenoble, FR, beamline ID30a1). For CKIa Structure Crystals of CSNK1A1 in complex with A86 were obtained using sitting drop vapor diffusion set-ups. CSNK1A1 at a concentration of 5.8 mg/ml (50 mM Tris-HCl, 300 mM NaCl, 0.25 mM TCEP, pH 8.0) was pre-incubated with 0.7 mM (4.7-fold molar excess) of Mg2+-ATP (150 mM in DMSO) for 1 h. 0.1 mL of the protein solution was then mixed with 0.1 mL of reservoir solution (0.10 M MES/NaOH pH 6.8, 10.0%(v/v) 2-propanol, 26.0%(v/v) PEG 400) and equilibrated at 4 C over 0.06 mL of reservoir solution. Well diffracting crystals appeared within 4 days and grew to full size over 23 days (Figure 1) . A 150 mM solution of A-86 in DMSO was diluted in 30% v/v PEG 400, 0.1 M MES/NaOH pH 6.8, 10% v/v 2-Propanol to 2 mM and 1 mL of the resulting solution was added to a 0.2 mL crystallization drop. Crystals were harvested after 90min and cryo-protected with Paratone-N. A complete 2.3 Å dataset of a CSNK1A1/A-86 crystal was collected at the ESRF synchrotron radiation source (Grenoble, FR, beamline ID30a1). Molecular replacement was done using a published structure of CSNK1A1 (pdb accession code 5FQD) as starting model. Several rounds of alternating manual re-building and refinement with REFMAC5 resulted in the final model. For CKId Structure Wild-type CKId protein with the mutation R13N was used for crystallization. Crystals of CK1d in complex with A86 were obtained using hanging drop vapor diffusion set-ups. CK1d at a concentration of 13.6 mg/ml (50 mM HEPES, 266 mM NaCl, 1 mM EDTA, 1 mM DTT, 5 mM b-OG, pH 7.5) was pre-incubated with 2 mM (5.1-fold molar excess) of A-86 (150 mM in DMSO) for 1 hr. 1 mL of the protein solution was then mixed with 1 mL of reservoir solution (0.1 M Na3-Citrate, pH 4.9, 18%(w/v) PEG 3350) and equilibrated at 20 C over 0.4 mL of reservoir solution. Well diffracting crystals appeared overnight. A complete 1.6 Å dataset of a CK1d/A-86 crystal was collected at the ESRF synchrotron radiation source (Grenoble, FR, beamline ID30a1). Molecular replacement was done using a published structure of CK1d (pdb accession code 3UYT) as starting model. Several rounds of alternating manual re-building and refinement with REFMAC5 resulted in the final model. For CDK9/Cyclin T1 Structure Crystals of CDK9/Cyclin T1 in complex with A-86 were obtained using sitting drop vapor diffusion set-ups. CDK9/Cyclin T1 at a concentration of 4.5 mg/ml (20 mM Tris / HCl, 250 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.3) was pre-incubated with 0.6 mM (5.1-fold molar excess) of A-86 (150 mM in DMSO) and 4 mM TCEP for 1 hr. 0.1 mL of the protein solution was then mixed 0.1 mL of reservoir solution (0.01 M Ca-Chloride, 0.1 M MES/NaOH, pH 6.50, 1.2 M Na-Acetate) and equilibrated at 4 C over 0.06 mL of reservoir solution. Crystals were obtained using microseeding. Well diffracting crystals appeared within 4 days and grew to full size over 8 days. A complete 3.2 Å dataset of a CDK9/A-86 crystal was collected at ESRF synchrotron radiation source (Grenoble, FR, beamline ID30a1). Molecular replacement was done using a published structure of CDK9/Cyclin T1 (pdb accession code 3BLH) as starting model. Several rounds of alternating manual re-building and refinement with REFMAC5 resulted in the final model.
All the structures were visualized using PyMOL (Version 1.8 Schrö dinger, LLC). Multiple Sequence Analysis was performed with Clustal Omega, using the sequences for the human CKI and CKII gene family members.
Ex vivo assays
Mice with advanced leukemia (> 80% GFP + in PB) were sacrificed and BM was flushed with PBS from the femur and tibia. Cells were treated with erythrocyte lysis buffer (NH 4 Cl 150 mM, KHCO 3 10 mM, EDTA 0.1 mM) and centrifuged (200g, 5 min). Pellet was resuspended in PBS, white blood cells (WBCs) were counted with an automatic Abacus Junior Vet (Diatron) followed by centrifugation. Cells were strained (70 mm sterile strainer) and resuspended with StemPro-34 SFM media (GIBCO) supplemented with 10 ng/ml of IL3, IL6, thyroid peroxidase (TPO), stem cell factor (SCF); StemPro-34 Nutrient Supplement (25 ml/ml), PenSrep (Sigma, 1:100) and L-glutamine (Sigma, 1:100). Cells were diluted to 1.5*10 5 cells in 0.15 mL media and plated with or without the specific inhibitors in a U bottom 96 well plate with lid (Bar-Naor) for 16 À18 hr. Inhibitors were dissolved in DMSO, and diluted 1:1000 to the final concentrations. Cells with DMSO only (diluted 1:1000) served as control. Incubation was done in a 5% CO 2 TC incubator. For rapid-hit experiments, cells were centrifuged at the indicated time intervals, resuspended with fresh media without inhibitors and further incubated for a total of 18 hr. The following day, cells were spun (300g, 5 min), washed and stained with Annexin V-PE (Biolegend, 1:100) and 7AAD (TONBO biosciences) in Annexin buffer (150 mM NaCL, 4 mM KCl, 1.5 mM CaCl 2 , 10mM HEPES and 0.75 mM MgCl 2 ). Cells were analyzed by Beckman coulter CytoFlex for GFP and PE.
CFU assay
Primary BM cells from WT and AML mice were harvested from the tibia and femur and treated as described above. WBCs were diluted in methylcellulose (MethoCult GF M3434; StemCell Technologies) supplemented with Gentamycin, Amphotericin B and PenStrep to a concentration of 2*10 4 cells/ml. Cells were plated in a 6 well TC dish, 1ml/well and incubated in a 5% CO 2 TC incubator for 7-9 days with the indicated concentrations of the indicated inhibitor. CFUs were visualized and photographed with an Olympus SZX16.
Histology and immunohistochemistry (IHC)
5 mm sections were cut onto a poly lysine coated glass slide from 4% formaldehyde fixed and paraffin embedded tissue. Bones were fixed in 4% formaldehyde then decalcified before paraffin embedding in HCl/EDTA based solution (RDF D1210 Anapath, StatLab medical products) for four hr at room temperature. Hematoxylin and Eosin (H&E) staining were performed by the Pathology Department of Hadassah Ein-Karem hospital by an automated system. Immunohistochemistry (IHC) for hCD45 and hc-Kit of PDX-3 samples was performed by automated BenchmarkUltra (Ventana Medical Systems) following standard procedures. Antibody staining was done with anti-human c-Kit (Cell MarQue #117R-16), anti-human CD45 (Dako #M0701) and at 1:200 and 1:250 dilutions, respectively. For cleaved caspase 3 staining sections were incubated with anti-cleaved caspase 3 (1:100; Cell Signaling Technology). ImmPRESS HRP Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit and 3,3 0 -Diaminobenzidine (DAB) chromogen (Lab Vision) were used for detection.
Blood Smear
Peripheral blood samples were smeared on a glass slide and were stained with Wright-Giemsa reagent by Hadassah Ein-Karem hospital Hematology Department.
Blood analysis
Peripheral venous blood was obtained from the mouse facial vein using standard techniques and analyzed using the auto hematology analyzer BC-2800 (Mindray) or an automatic Abacus Junior Vet (Diatron), following manufacturer's instructions.
Flow cytometry FACS analysis was performed with BECKMAN COULTER (CytoFLEX). Sorting was performed by FACS ARIA sorter. For immunostaining, cells were suspended in a 1% BSA/PBS buffer with 5mM EDTA. For viability staining, cells were suspended in Annexin buffer and stained for Annexin V (Biolegend) and 7AAD (TONBO biosciences). For human samples, blocking was done with 20% human serum. FACS analysis for PDX-2 was done on live cells (propidium iodide (MBL #4700-200) negative or 7AAD negative) with the following antibodies: anti-hCD45-PB (eBioscience #304022), anti-hCD33-PE/Cy7 (Biolegend #366617), anti-hCD38-APC (Biolegend #356606) and anti-mCD45.1-FITC (Biolegend #110706). All antibodies used at 1:250 dilutions.
Antibodies used for HSC staining Lineage cocktail-Biotin (Miltenyibiotec), c-Kit APC-eFluor780 (eBioscience), Sca-1 PE-Cy7 (eBioscience), Flt3 -APC (eBioscience), CD34 -eFluor450 (eBioscience), c-Kit-PE (Biolegend), strepavidin-percp/cy5.5 (eBioscience). The stem cell compartments were defined as following: LT-HSC, Lin Human shRNA sequences ShCKIa (in Plko vector):
Western blot analysis Proteins were extracted by whole-cell-extract protocols from cell pellets in RIPA buffer containing proteases and phosphatase inhibitors. Western blot analysis was performed by means of standard techniques. Blots were incubated with antibodies detecting b-catenin (1:2,500; BD Transduction Laboratories), phospho Ser45-b-catenin (1:750; Cell Signaling), phospho Ser33/Ser37/Thr41-b-catenin (1:750; Cell Signaling), phospho-Thr41/Ser45-b-catenin (1:750; Cell Signaling); CKIa (1:1000; Santa Cruz), Hsp90a (1:5000; Calbiochem), aTubulin (1:5000; Sigma), mouse p53 (1:1000; Cell Signaling), Cleaved Caspase 3 (1:750; Cell Signaling), c-Myc (1:750; Cell Signaling), MCL-1 (1:1000; Cell Signaling), human p53 (DO-1/1801 hybridoma mix; 1:20), MDM2 (2A9/4B2/ 4B11 hybridoma mix; 1:40), phospho-Histone H2A.X (Ser139; 1:1000; Millipore), PP2Ac (1:1000; rabbit serum kindly provided by David Virshup), Cyclin D1 (1:500; Lab Vision), Phospho-Rpb1 CTD (Ser 2/5; 1:1000; Cell Signaling), Phospho-Rpb1 CTD (Ser2; 1:1000; abcam), Phospho-Rpb1 CTD (Ser5; 1:1000; Merck). Secondary antibodies were HRP-linked goat anti-mouse, goat anti-rabbit and rabbit anti-goat (all 1:10,000; Jackson). Blots were developed using ECL (GE Healthcare).
RT-qPCR analysis
Total RNA was extracted from cell pellets using miRNeasy Kit (QIAGEN) and subjected to reverse transcription with qScript cDNA Synthesis Kit (QIAGEN). mRNA expression levels were measured by RT-qPCR using SYBR-Green (Invitrogen) in a QuantStudio 12 K Flex. Relative quantities of gene transcripts were analyzed in qBase software, and normalized to GAPDH transcripts. Sequences of RT-PCR primers are listed in the extended data information.
qPCR primers used in this study . Sonicated lysates were centrifuged at 13,000 rpm for 5 mins and the chromatin was incubated overnight at 4 C with the anti-H3K27ac immune-beads, or with the anti-RNA polymerase II CTD (phospho S2) immune-beads. Following chromatin immunoprecipitation (ChIP), samples were washed, and bound complexes were eluted by Direct Elution Buffer (10 mM Tris-HCl pH-8, 0.3 M NaCl, 5 mM EDTA and 0.5% SDS), reverse cross-linked and treated with RNase A (ThermoFisher) and Proteinase K (Invitrogen). Chromatin was purified with QIAquick Gel Extraction Kit (QIAGEN) and processed for ChIP Seq. Immunoprecipitation performed with anti-IgG control yielded very low signal (not shown). Libraries for Illumina sequencing were prepared using TruSeq nano DNA sample prep kit (Illumina) using 50 ng of immunoprecipitated DNA as starting point. Libraries were prepared according to manufacturer's instructions, quantified by Qubit (Invitrogen) and TapeStation (Agilent) and sequenced on an Illumina HiSeq2500 (50 SR lane V4 reagents).
ChIP-seq data processing Sequence alignment and Peak identification Following read duplication removal (picard-tools), all datasets were individually aligned to the mouse genome (GRCm38/mm10) using Bowtie2 (Langmead and Salzberg, 2012) with default parameters. Next, peaks were called on the aligned BAMs from each IP replicate using MACS2 with the relevant input sample (either AML or WT), a q-value threshold of 0.01, and MFOLD of 5 50. Pileup fragment profiles per million reads were generated by MACS2 using the SPMR parameter and were used for visualization of ChIP-seq data directly on the UCSC genome browser. Super Enhancer identification H3K27ac super-enhancers (SEs) and typical enhancers (TEs) were mapped using the ROSE software package (http://younglab.wi. mit.edu/super_enhancer_code.html) with a default stitching distance of 12.5Kb and a TSS exclusion zone of 2.5Kb. For Figure 4E , genes associated with super-enhancers were identified as those lying closest to a 50Kb window by ROSE geneMapper tool.
Quantifying Effects of A51 Treatment on Transcription Elongation
We quantified the effects of A51 treatment on transcription elongation of genes by measuring the change in pSer2 CTD density in whole gene body. The Log2 fold change in RNA Pol II density ± A51 treatment was calculated for all genes overlapping TE or SE by up to 5Kb. Fold change and differential binding analysis To determine the log2 fold change of H3K27ac or pSer2 binding levels in DMSO versus A51-treated samples, we used the Bioconductor R package DiffBind (Stark and Brown, 2011) . DiffBind was used on either typical enhancers or super-enhancers called by MACS and ROSE as explained above. The analysis was run wither in triplicates, for H3K27ac, or in duplicates, for pSer2. DiffBind was run using the DESeq2 method.
Chemical synthesis procedures Preparation of (E)-1-cyclopropyl-4-(dimethylamino)-3-(2-(methylthio)pyrimidin-4-yl)but-3-en-2-one (Core A)
Step 1: N, O-Dimethylhydroxylamine hydrochloride (25.14 g, 257.69 mmol, 1.72 eq), HATU (56.97 g, 149.82 mmol, 1.00 eq) and TEA (45.48 g, 449.46 mmol, 3 .00 eq) were added to a solution of 2-cyclopropylacetic acid (15.00 g, 149.82 mmol, 1.00 eq) in DCM (500 mL) at 0 C, and then the mixture was stirred at 30 C for 3 h. The resulting mixture was poured into water (500 mL). The aqueous washing phase was extracted with DCM (3*250 mL). The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography (SiO 2 , petroleum ether(PE): ethyl acetate (EA) = 50:1 to 10:1) to give the desired compound 2 (13.20 g, 82.97 mmol, 55.4% yield) as colorless liquid. Step 2: To a solution of 4-methyl-2-methylsulfanyl-pyrimidine (9.00 g, 64.19 mmol, 1.00 eq) in THF (500 mL) was added LDA (2 M, 48.46 mL, 1.51 eq) at À78 C. After stirring for 1 h, a solution of compound 2 (13.79 g, 96.29 mmol, 1.50 eq) in THF (500 mL) was added drop wise at À78 C and then the reaction mixture was stirred at À78 C for 4 h. Quenched with saturated aq. NH 4 Cl (100 mL), the aqueous phase was extracted with ethyl acetate (3 3 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was crystallized from petroleum ether/ethyl acetate to afford the desired compound 4 (13.60 g, 55.06 mmol, 85.8% yield) as a yellow solid.
LCMS Step 1: A solution of Core A (6.20 g, 22.35 mmol, 1.00 eq) and methylhydrazine (8.00 g, 69.46 mmol, 3.11 eq) in ethanol (100 mL) was stirred at 90 C for 16 hr. The solvent was removed in vacuum. The residue was purified by pre-HPLC (basic condition) to afford compound 5 (1.80 g, 6.84 mmol, 30.6% yield) as a yellow solid and the isomer 5A (2.00 g, 7.30 mmol, 32.6% yield) as a yellow oil.
Compound 5 Step 2: To a solution of compound 1 (1.50 g, 5.76 mmol, 1.00 eq) in DCM (20 mL) was added m-CPBA (2.98 g, 17.28 mmol, 3.00 eq) at 0 C and stirred at 30 C for 2 hr. The resulting mixture was washed with NaHSO 3 (2 3 100 mL), saturate aq. NaHCO 3 (100 mL) and brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by column chromatography on silica gel (petroleum ether: ethyl acetate = 10:1 to 1:1) to give the compound Core C (1.50 g, 5.08 mmol, 88.2% yield) as a yellow solid. The reaction mixture of amine n (1.20 eq) and Core C (1.00 eq) in dioxane (3 mL) was stirred at 130 C under microwave for 1.5 h. The reaction mixture was poured into H 2 O (20 mL). The aqueous layer was extracted EA (20 mL*3). The combined organic layers were washed with brine (20 mL*3), dried over Na 2 SO 4 , filtered and concentrated. Step 1: To a solution of compound N-methylpyrazole (51_1, 8.00 g, 97.44 mmol, 1.00 eq) in THF (160 mL) was added drop-wise n-BuLi (2.5 M, 46.77 mL, 1.20 eq) at À78 C. After the resulting mixture was stirred for 1hr at that temperature, the solution of cyclopropanecarbaldehyde (8.20 g, 116.93 mmol, 1.20 eq) in THF (80 mL) was added drop-wise. And then the reaction mixture was stirred at 20 C for 16 h. TLC (PE:EA = 2:1) showed reactant 1 (Rf = 0.3) was consumed and product (Rf = 0.05) was formed. The mixture was poured into aqueous NH 4 Cl (300 mL) and stirred for 10 min. The aqueous phase was extracted with ethyl acetate (100 mL*2). The combined organic phase was washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO 2 , PE:EA = 8:1$0:1) to afford compound 51_3 (12.00 g, 78.85 mmol, 80.9% yield, 100% purity) as a colorless oil.
LCMS: RT = 0.118 min, m/z 153.1 [M+H]
+
Step 2: The reaction mixture of compound 51_3 (9.00 g, 59.14 mmol, 1.00 eq), TFA (40.46 g, 354.84 mmol, 26.27 mL, 6 .00 eq) and Et 3 SiH (41.26 g, 354.84 mmol, 56.52 mL, 6 .00 eq) in DCM (900 mL) was stirred at 40 C for 36h. The mixture was adjusted to pH = 8 with aqueous NaHCO 3 and separated. The organic layer was concentrated and purified by prep HPLC (basic condition) to give compound 51_5 (2.10 g, 15.42 mmol, 26.1% yield) as a dark brown oil.
LCMS: RT = 0.565 min, m/z 137. (m, 2H).
Step 4: To a solution of compound 51_6 (3.00 g, 13.95 mmol, 1.00 eq) in THF (60 mL) was added n-BuLi (2 M, 10.46 mL, 1.50 eq) drop-wise at À78 C. After stirring for 0.5h at that temperature, a solution of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5.19 g, 27.90 mmol, 2.00 eq) in THF (6 mL) was added. The resulting mixture was warmed to 20 C and stirred for 0.5h. TLC (PE:EA = 5:1) showed reactant (Rf = 0.6) was consumed and product (Rf = 0.5) was formed. The mixture was quenched with saturated NH 4 Cl (50 mL) and extracted with EA (100 mL). The organic layer was concentrated and purified by column chromatography (SiO 2 , PE:EA = 20:1$10:1) to give compound 51_ 7 (3.30 g, 11.40 mmol, 81.7% yield, 90.5% purity) as a colorless oil.
LCMS Step 5: To a solution of compound 51_ 7 (500.00 mg, 1.91 mmol, 1.00 eq) in DME (10 mL) were added 2, 4, 5-trichloropyrimidine (51_8, 420.40 mg, 2.29 mmol, 1.20 eq), Na 2 CO 3 (2 M, 2.10 mL, 2.20 eq) and catalyst PdCl 2 (Amphos) 2 (67.62 mg, 95.50 mmol, 0.05 eq) under nitrogen. The resulting mixture was stirred at 85 C for 2hr under nitrogen. TLC (PE:EA = 5:1) showed reactant (Rf = 0.4) was consumed and product (Rf = 0.5) was formed. The mixture was diluted with water (50 mL) and extracted with EA (50ml). The organic layer was concentrated and purified by silica gel column (PE:EA = 5:1) to afford compound 51_9 (350.0 mg, 1.05 mmol, 55% yield, 85% purity) as a yellow oil.
LCMS: RT = 0.819 min, m/z 283.1 [M+H]
Step 6: The reaction mixture of compound 51_9 (300.00 mg, 1.06 mmol, 1.00 eq) and trans-cyclohexane-1, 4-diamine (484.17 mg, 4.24 mmol, 4.00 eq) in dioxane (4.5 mL) was stirred at 130 C for 2h under microwave. The mixture was filtered and concentrated. Step 1: To a solution of 64_1 (2.00 g, 9.29 mmol, 1.00 eq) in DCM (20 mL) were added TEA (1.88 g, 18.58 mmol, 2.58 mL, 2.00 eq) and methanesulfonyl chloride (1.06 g, 9.29 mmol, 719.03 mL, 1.00 eq) at 0 C. The mixture was stirred at 20 C for 2 hr. The mixture was diluted with H 2 O (30 mL) and extracted with DCM (20 mL*2). The combined organic layers were dried and concentrated to give 64_2 (2.50 g, 8.52 mmol, 91.7% yield) as a white solid. Step 2: To a solution of 1H-pyrazole (195.25 mg, 2.87 mmol, 1.20 eq) in MeCN (7.00 mL) were added Cs 2 CO 3 (1.56 g, 4.78 mmol, 2.00 eq) and 64_2 (700.00 mg, 2.39 mmol, 1.00 eq). The mixture was stirred at 100 C for 2 hr. The mixture was diluted with H 2 O (20 mL) and extracted with EtOAc (10 mL*3). The combined organic layers were washed with brine (20 mL) and concentrated. The residue was purified by pre-HPLC (basic condition) to give 64_ 3(200.00 mg, 732.25 mmol, 30.6% yield, 97.1% purity) as a yellow solid.
MS: m/z RT = 0.888 min, 266.0 [M+H]
Step 3: To a solution of 64_3 (180.00 mg, 678.35 mmol, 1.00 eq) in DCM (2 mL) was added TFA (400.00 mL) at 0 C. The mixture was stirred at 20 C for 1 hr. The mixture was diluted with H 2 O (30 mL) and extracted with DCM (10 mL*2). Step 4: To a solution of 51_9 (100.00 mg, 353.16 mmol, 1.00 eq) in DMSO (1.5 mL) were added amine-64 (95.48 mg, 529.74 mmol, 1.50 eq) and DIEA (182.57 mg, 1.41 mmol, 246.71 mL, 4.00 eq). The resulting mixture was stirred at 160 C for 3 hr, filtered and the mother liquid was concentrated. The residue was purified by pre-HPLC (basic condition) and then prep-HPLC (HCl condition) to give A-64 (10.00 mg, 23.42 mmol, 6.6% yield, 100% purity) as a yellow solid.
LCMS 
To a solution of A-51 (200.00 mg, 554.20 mmol, 1.00 eq) and 1H-pyrazole-4-carbaldehyde (53.25 mg, 554.20 mmol, 1.00 eq) were added AcOH (34.86 mL, 609.62 mmol, 1.10 eq) and NaBH 3 CN (69.65 mg, 1.11 mmol, 2.00 eq). The mixture was sitrred at 15 C for 16 hr. The mixture was quenched with aqueous NaHCO 3 (1 mL) and concentrated. Step 1: To a solution of compound 51_7 (800 mg, 3.05 mmol, 1.00 eq) in DME (16 mL) were added compound 2 (509.54 mg, 3.05 mmol, 1.00 eq), Na 2 CO 3 (2 M, 4.6 mL, 3.00 eq) and 4-ditert-butylphosphanyl-N,N-dimethyl-aniline;dichloropalladium (108.04 mg, 152.50 mmol, 108 uL, 0.05 eq) under nitrogen. The resulting mixture was stirred at 85 C for 2 hr under nitrogen. The mixture was diluted with H 2 O (50 mL) and extracted with EA (50 mL). The organic layer was concentrated to give compound 86_1 (1.20 g, crude) as a yellow oil.
LCMS: RT = 1.819 min, m/z 267.1 [M+H]
Step 2: The mixture of compound 86_1 (1.10 g, 4.12 mmol, 1.00 eq) and compound 4 (1.88 g, 16.48 mmol, 4.00 eq) in dioxane (16 mL) was stirred at 130 C for 8 hr under microwave. The mixture was filtered and concentrated. The residue was purified by pre-HPLC (HCl condition) to give A-86 (1.30 g, crude) as a yellow solid. A-86 (300 mg) was purified again by prep-HPLC (HCl condition) to give A-86 (20.00 mg, 52.51 mmol, 12.1% yield, 100% purity, HCl) as a yellow solid.
LCMS: RT = 2.321 min, m/z 345.2 [M+H] + Preparation of (S)-3-(4-methyl-1-oxoisoindolin-2-yl)azepane-2,7-dione (BTX161) Scheme.
Step 1 To a solution of methyl 2,3-dimethylbenzoate (1) (18.0 g, 109.6 mmol) in Carbon Tetrachloride (250 mL) at room temperature was added N-Bromosuccinimide (NBS) (23.4 g, 131.52 mmol). The reaction was heated to 85 C for 5 min. Then 2,2 0 -azobis(2-methylpropionitrile) (AIBN) (9.42 g, 54.8 mmol) was added and the reaction was stirred at 85 C for 16 hr. The reaction was cooled to room temperature and the solid was filtered off. The filtrate was concentrated to give the crude product, which was purified by silica-gel column chromatography eluting with Ethyl acetate / Petroleum ether from 0/1 to 1/50 to give crude methyl 2-(bromomethyl)-3-methylbenzoate (2) (23.4 g, yield: 87.8%) as a colorless oil. MS m/z 243.7 [M+] .
Step 2
To a solution of methyl 2-(bromomethyl)-3-methylbenzoate (2) (23.4 g, 96.57 mmol) in N,N-dimethylformamide (300 mL) at room temperature was added (S)-3-aminoazepan-2-one (3) (12.36 g, 96.57 mmol). Then triethylamine (19.5 g, 193. 14 mmol) was added, and the resulting mixture was heated to 50 C for 16 hr. The reaction was cooled to room temperature and the solvent was removed. The residue was diluted with water (100 mL). The suspension was stirred at room temperature for 20 min. The solid was filtered off and the solid was triturated with Ethyl acetate to give (S)-4-methyl-2-(2-oxoazepan-3-yl)isoindolin-1-one (4) To a solution of (S)-4-methyl-2-(2-oxoazepan-3-yl)isoindolin-1-one (4) (5.8 g, 22.48 mmol) in Acetonitrile (300 mL) and wet DMSO (15 mL) at 0 C was added Dess-martin periodinane reagent (23.8 g, 56.2 mmol). The suspension was heated at 85 C for 16 hr. The reaction was cooled to room temperature and 100 mL of a saturated sodium thiosulfate solution was added followed by stirring for 5 min. The resulting mixture was extracted with Dichloromethane (30 mL x 2) and the combined solution was washed with 10% aq. Sodium thiosulfate / aq. Sodium bicarbonate (1:1 mixture) (50 mL) and brine. The organic layer was dried over Sodium sulfate, filtered and concentrated to afford the crude product, which was purified by silica-gel column chromatography eluting with Ethyl acetate / Petroleum ether from 1/2 to 1/1 to give the white solid. The solid was triturated with Methanol to give (S)-3-(4-methyl-1-oxoisoindolin-2-yl)azepane-2,7-dione (720 mg, yield: 11.8%) as a white solid. 
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed by GraphPad Prism software. For survival studies the log-rank test was used to compare differences between the survival of two groups. For all in vitro, ex vivo, and in vivo experiments, unpaired two-tailed Student's t test was used, except for Figure 1A where Mann-Whitney non-parametric test was used. Data are shown as mean ± SD as indicated in the figure legends. For bioinformatics analysis comparing pSer2 CTD ChIP-seq in SEs versus TEs ( Figure 5E ) we used Welch's two-tailed t test as this is the standard test for this model. Statistical significance is as follows: ns p > 0.05, * p % 0.05, ** p % 0.01, *** p % 0.001. For each in vivo experiment number of mice (n) is indicated. For in vitro and ex vivo experiments number of technical or biological repeats is indicated in the figure legends.
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